SRF 231

Drug Profile

SRF 231

Alternative Names: anti-CD-47 mAb-Surface Oncology; anti-CD-47 monoclonal antibody-Surface Oncology; CD47-mAb SRF-231; SRF-231

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Surface Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action CD47 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 30 Jul 2018 SRF 231 receives Orphan Drug status for Multiple myeloma in USA
  • 21 Mar 2018 Phase-I clinical trials in Haematological malignancies (Late-stage disease) in USA (unspecified route)
  • 21 Mar 2018 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top